Furthermore, NFAT5 acts as a tumor suppressor in HBV-associated HCC tissues by suppressing DARS2 expression, indicating that DARS2 may be a potential target for the treatment and diagnosis of HCC (Qin et al., 2017). Here, DARS2 is linked to neoplasm.